ATE428790T1 - Verbessertes system zur regulation der transgenexpression - Google Patents

Verbessertes system zur regulation der transgenexpression

Info

Publication number
ATE428790T1
ATE428790T1 AT01977218T AT01977218T ATE428790T1 AT E428790 T1 ATE428790 T1 AT E428790T1 AT 01977218 T AT01977218 T AT 01977218T AT 01977218 T AT01977218 T AT 01977218T AT E428790 T1 ATE428790 T1 AT E428790T1
Authority
AT
Austria
Prior art keywords
improved system
transgene expression
regulating transgene
regulating
inducer
Prior art date
Application number
AT01977218T
Other languages
English (en)
Inventor
Ronald Abruzzese
Vidya Mehta
Jeffrey Nordstrom
Jason G Fewell
Original Assignee
Genetronics Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc, Baylor College Medicine filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE428790T1 publication Critical patent/ATE428790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Eye Examination Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Mushroom Cultivation (AREA)
  • Paper (AREA)
AT01977218T 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression ATE428790T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23503000P 2000-09-25 2000-09-25
US26078101P 2001-01-10 2001-01-10
US27828101P 2001-03-23 2001-03-23
PCT/US2001/030305 WO2002024899A2 (en) 2000-09-25 2001-09-25 Improved system for regulation of transgene expression

Publications (1)

Publication Number Publication Date
ATE428790T1 true ATE428790T1 (de) 2009-05-15

Family

ID=27398677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977218T ATE428790T1 (de) 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression

Country Status (7)

Country Link
US (1) US7579326B2 (de)
EP (1) EP1326969B1 (de)
AT (1) ATE428790T1 (de)
AU (1) AU2001296354A1 (de)
CA (1) CA2423093C (de)
DE (1) DE60138404D1 (de)
WO (1) WO2002024899A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US9453219B2 (en) * 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
CA2580515C (en) * 2004-10-04 2017-05-02 National Research Council Of Canada Expression system, components thereof and methods of use
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP1891224A1 (de) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta-gentherapie unter verwendung eines verbesserten, regulierten expressionssystems
WO2006122971A2 (en) * 2005-05-19 2006-11-23 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
WO2007134906A1 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
WO2010042189A2 (en) * 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
JP2018518511A (ja) * 2015-06-26 2018-07-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 細胞質ｄｎａ監視分子の調節方法
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2017117248A1 (en) * 2015-12-28 2017-07-06 Colorado State University Research Foundation Compositions and methods for detection of small molecules
EP3411483B1 (de) * 2016-02-05 2022-07-06 PolyGene AG Glucocorticoid-basiertes genregulationssystem
EP3235516B1 (de) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulierbarer adeno-assoziierter virus (aav)-vektor
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11780902B1 (en) 2018-07-20 2023-10-10 Colorado State University Research Foundation Receptor/histidine kinase fusion constructs and uses thereof
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN114072166A (zh) 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
US20230089312A1 (en) * 2020-02-25 2023-03-23 University Of Massachusetts Inducible single aav system and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS62171696A (ja) 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
AU633045B2 (en) 1988-12-23 1993-01-21 Salk Institute For Biological Studies, The Receptor transcription-repression activity compositions and methods
CA2057049A1 (en) 1989-05-26 1990-11-27 Ronald M. Evans Dominant negative members of the steroid/thyroid superfamily of receptors
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US6416998B1 (en) * 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
ATE371736T1 (de) * 1996-10-29 2007-09-15 Baylor College Medicine Modifizierte steroid-hormon rezeptoren
JP2001512142A (ja) 1997-07-31 2001-08-21 カイロン コーポレイション 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
GB9718591D0 (en) * 1997-09-03 1997-11-05 Zeneca Ltd Methods
KR20010040309A (ko) * 1997-12-23 2001-05-15 스티븐 에이. 서윈. 엠.디. 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법
GB9817660D0 (en) 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
AU1523900A (en) * 1998-11-20 2000-06-13 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use

Also Published As

Publication number Publication date
DE60138404D1 (de) 2009-05-28
CA2423093A1 (en) 2002-03-28
US20030220286A1 (en) 2003-11-27
WO2002024899A3 (en) 2002-12-12
US7579326B2 (en) 2009-08-25
AU2001296354A1 (en) 2002-04-02
EP1326969A2 (de) 2003-07-16
CA2423093C (en) 2013-09-17
EP1326969B1 (de) 2009-04-15
WO2002024899A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE428790T1 (de) Verbessertes system zur regulation der transgenexpression
ATE439440T1 (de) Sirna-vermitteltes gen-silencing von alpha- synuklein
DE60144434D1 (de) Mehrfach-induzierbares genregulierungssystem
DK1354034T3 (da) Transgene transchromosomale gnavere til fremstilling af humane antistoffer
DE60037752D1 (de) Biologische kontrolle mittels konditionell-dominant-lethalem genetischen system
DE69925410D1 (de) Erweiterung des Befehlssatzes unter Verwendung von Präfixcode
DE60232245D1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
HRP20050705B1 (hr) Ekspresijski vektor koji sadrži promotor mcmv ie2
BRPI0413024A (pt) sistema de expressão de gene de inseto, promotor, vetor, inseto e, método para estabelecer compatibilidade de um promotor com uma espécie
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
ATE390125T1 (de) Formulierung für einen dosierinhalator unter verwendung von hydro-fluoro-alkanen als treibstoffe
DE602004030315D1 (de) Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
DE50210608D1 (de) Vorrichtung zur kontrolle von material
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
ATE543502T1 (de) Allomon-abstossungsmittel zur kontrolle von arachnidae
DE60128830D1 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
DK1210446T3 (da) Modificeret ubiquitin-regulatorisk system
EP1642969A4 (de) Fluoreszenzprotein und pigmentprotein
FR2827169B1 (fr) Durcisseur pour les ongles
ATE334592T1 (de) Biologische bekämpfung von nematoden
DK1368480T3 (da) Fremgangsmåde til ændring af genomet i grampositive bakterier ved hjælp af et nyt konditionalt negativt dominant markörgen
DE50214936D1 (de) Verwendung des adenoviralen e2-late-promotors
DE50008241D1 (de) Metallschaumkörper auf basis von zink
ATE273394T1 (de) Wirts-vektor-systeme zur phosphatregulierten überproduktion von polypeptiden in bacillus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties